CY1124215T1 - Μκ2 αναστολεις και χρησεις αυτων - Google Patents
Μκ2 αναστολεις και χρησεις αυτωνInfo
- Publication number
- CY1124215T1 CY1124215T1 CY20211100504T CY211100504T CY1124215T1 CY 1124215 T1 CY1124215 T1 CY 1124215T1 CY 20211100504 T CY20211100504 T CY 20211100504T CY 211100504 T CY211100504 T CY 211100504T CY 1124215 T1 CY1124215 T1 CY 1124215T1
- Authority
- CY
- Cyprus
- Prior art keywords
- inhibitors
- compositions
- methods
- present
- provides compounds
- Prior art date
Links
- 229940124789 MK2 inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051788P | 2014-09-17 | 2014-09-17 | |
| US201562199927P | 2015-07-31 | 2015-07-31 | |
| PCT/US2015/050495 WO2016044463A2 (en) | 2014-09-17 | 2015-09-16 | Mk2 inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124215T1 true CY1124215T1 (el) | 2022-05-27 |
Family
ID=55454109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100504T CY1124215T1 (el) | 2014-09-17 | 2021-06-09 | Μκ2 αναστολεις και χρησεις αυτων |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US9458175B2 (https=) |
| EP (2) | EP3912981A1 (https=) |
| JP (3) | JP6556225B2 (https=) |
| KR (1) | KR102457848B1 (https=) |
| CN (1) | CN106998692B (https=) |
| AU (1) | AU2015317741B2 (https=) |
| BR (1) | BR112017005266B1 (https=) |
| CA (1) | CA2961607C (https=) |
| CL (1) | CL2017000576A1 (https=) |
| CO (1) | CO2017003279A2 (https=) |
| CY (1) | CY1124215T1 (https=) |
| DK (1) | DK3193611T3 (https=) |
| EA (1) | EA037299B1 (https=) |
| EC (1) | ECSP17023281A (https=) |
| ES (1) | ES2874561T3 (https=) |
| HR (1) | HRP20210529T1 (https=) |
| HU (1) | HUE054347T2 (https=) |
| IL (1) | IL251051B (https=) |
| LT (1) | LT3193611T (https=) |
| MA (1) | MA40534B1 (https=) |
| MX (2) | MX373341B (https=) |
| PL (1) | PL3193611T3 (https=) |
| PT (1) | PT3193611T (https=) |
| RS (1) | RS62017B1 (https=) |
| SA (1) | SA517381115B1 (https=) |
| SG (2) | SG11201701861RA (https=) |
| SI (1) | SI3193611T1 (https=) |
| SM (1) | SMT202100311T1 (https=) |
| TW (1) | TWI744217B (https=) |
| WO (1) | WO2016044463A2 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2908098A1 (en) | 2013-03-15 | 2014-09-25 | Celgene Avilomics Research, Inc. | Mk2 inhibitors and uses thereof |
| RS62017B1 (sr) | 2014-09-17 | 2021-07-30 | Celgene Car Llc | Mk2 inhibitori i njihova upotreba |
| CN106632077B (zh) * | 2016-10-10 | 2019-01-22 | 上海再启生物技术有限公司 | 一种2-氨基-4-溴嘧啶的制备方法 |
| US11098057B2 (en) * | 2017-03-16 | 2021-08-24 | Celgene Car Llc | 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof |
| WO2018170200A1 (en) * | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Heteroaryl compounds useful as mk2 inhibitors |
| US10882867B2 (en) | 2017-03-16 | 2021-01-05 | Celgene Car Llc | Forms and compositions of a MK2 inhibitor |
| WO2018170203A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Mk2 inhibitors, synthesis thereof, and intermediates thereto |
| EP3596085A4 (en) * | 2017-03-16 | 2020-11-25 | Celgene CAR LLC | DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES |
| CN107058259A (zh) * | 2017-05-18 | 2017-08-18 | 南京中医药大学 | 分子标志物mk2基因及其应用 |
| WO2020072580A1 (en) * | 2018-10-02 | 2020-04-09 | Disc Medicine, Inc. | Matriptase 2 inhibitors and uses thereof |
| WO2020236636A1 (en) * | 2019-05-17 | 2020-11-26 | Celgene Car Llc | Methods of treating a mk2-mediated disorder |
| KR20220154094A (ko) * | 2020-02-14 | 2022-11-21 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | Ulk1/2 억제제를 이용한 단일 및 병용 요법 |
| KR20220153582A (ko) | 2020-02-14 | 2022-11-18 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 마크로시클릭 ulk1/2 억제제 |
| US20230087078A1 (en) * | 2020-03-02 | 2023-03-23 | Washington University | Compositions and methods for the treatment of pancreatic cancer |
| KR20230044446A (ko) * | 2020-07-24 | 2023-04-04 | 브리스톨-마이어스 스큅 컴퍼니 | 급성 호흡기 장애의 치료 방법 |
| JP2023550347A (ja) * | 2020-11-12 | 2023-12-01 | アクティーヴァ セラピューティクス， インコーポレイテッド | 血管漏出障害および内皮バリア障害を処置することにおける使用のためのｍｋ２活性化化合物 |
| CN116670142A (zh) * | 2021-02-01 | 2023-08-29 | 细胞基因公司 | Mk2抑制剂、其合成和其中间体 |
| EP4079855A1 (en) * | 2021-04-20 | 2022-10-26 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Compound and method for the prophylaxis and treatment of leukemia |
| WO2023025298A1 (zh) * | 2021-08-27 | 2023-03-02 | 瑞石生物医药有限公司 | 喹啉并呋喃衍生物及其用途 |
| EP4464694A4 (en) | 2022-01-14 | 2026-04-01 | Shanghai Hansoh Biomedical Co Ltd | POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE |
| WO2024044731A1 (en) * | 2022-08-26 | 2024-02-29 | Matchpoint Therapeutics Inc. | Diazepino-thieno-quinoxaline compounds and their use in therapy |
| EP4608401A2 (en) * | 2022-10-27 | 2025-09-03 | Bristol-Myers Squibb Company | Mk2 inhibitors and uses thereof |
| JP2026505836A (ja) * | 2023-02-07 | 2026-02-18 | セルジーン コーポレーション | Ｍｋ２キナーゼ分解剤として有用である化合物および組成物 |
| WO2024229401A2 (en) * | 2023-05-04 | 2024-11-07 | Matchpoint Therapeutics Inc. | Diazepino-thieno-quinoxaline compounds and their use in therapy |
| CN121368484A (zh) * | 2023-06-26 | 2026-01-20 | 深圳信立泰药业股份有限公司 | 一种mk2抑制剂在制备预防和/或治疗疾病药物中的应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5015778A (en) | 1989-12-18 | 1991-05-14 | The Dow Chemical Company | Catalytic method to produce hydroxy substituted arylophenones |
| ES2293638T3 (es) | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| US5441946A (en) | 1994-04-14 | 1995-08-15 | Rhone-Poulenc-Rorer Pharmaceuticals, Inc. | Phosphonate derivatives of lipophilic amines |
| GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| US6861440B2 (en) * | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
| TW200413273A (en) | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| ZA200504898B (en) | 2002-12-20 | 2006-11-29 | Pharmacia Corp | Acyclic pyrazole compounds |
| EP1663204B1 (en) | 2003-08-29 | 2014-05-07 | Exelixis, Inc. | C-kit modulators and methods of use |
| US20060106020A1 (en) | 2004-04-28 | 2006-05-18 | Rodgers James D | Tetracyclic inhibitors of Janus kinases |
| JP4734346B2 (ja) | 2005-02-04 | 2011-07-27 | セノミックス インコーポレイテッド | 連結ヘテロアリール部分を含む化合物、ならびに食用組成物のための新規なうまみフレーバー改変剤、味物質および味覚増強剤としての使用 |
| EP1849781A1 (en) | 2006-04-28 | 2007-10-31 | Laboratorios del Dr. Esteve S.A. | Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments |
| EP2223925A1 (en) | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| MX2009014247A (es) | 2007-07-16 | 2010-01-28 | Novartis Ag | Compuestos heterociclicos utiles como inhibidores de mk2. |
| AU2008317057B8 (en) | 2007-10-22 | 2014-02-13 | Merck Sharp & Dohme Corp. | Bicyclic Heterocycle Derivatives and their use as modulators of the activity of GPR119 |
| NZ603525A (en) | 2008-06-27 | 2015-02-27 | Celgene Avilomics Res Inc | Pyrimidine based compound and uses thereof |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| US20110269744A1 (en) * | 2010-03-12 | 2011-11-03 | Astellas Pharma Inc. | Benzazepine Compound |
| WO2011153553A2 (en) * | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| EP2508511A1 (en) | 2011-04-07 | 2012-10-10 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| EP2511273B8 (en) * | 2011-04-15 | 2019-06-26 | Hivih | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
| CN104136576B (zh) | 2012-02-22 | 2020-10-16 | 默克专利股份有限公司 | 液晶介质 |
| WO2013146963A1 (ja) * | 2012-03-28 | 2013-10-03 | 武田薬品工業株式会社 | 複素環化合物 |
| TW201406758A (zh) * | 2012-06-28 | 2014-02-16 | Daiichi Sankyo Co Ltd | 三環性化合物 |
| WO2014011902A1 (en) * | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| EA201590644A1 (ru) * | 2012-09-24 | 2015-09-30 | Клермонт Спиде | Способ и система с управляемыми мобильным отправителем доступом к данным и удалением данных |
| TW201417817A (zh) * | 2012-09-25 | 2014-05-16 | Daiichi Sankyo Co Ltd | Ｇｓｋ３抑制劑與抗ｄｒ５抗體之組合 |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| CA2908098A1 (en) | 2013-03-15 | 2014-09-25 | Celgene Avilomics Research, Inc. | Mk2 inhibitors and uses thereof |
| WO2015050957A2 (en) | 2013-10-02 | 2015-04-09 | Treatments For Systemic Lupus Erythematosus | Treatments for systemic lupus erythematosus |
| WO2016032882A1 (en) | 2014-08-25 | 2016-03-03 | Stc.Unm | Inhibition of mk2 in the treatment of cancer |
| RS62017B1 (sr) | 2014-09-17 | 2021-07-30 | Celgene Car Llc | Mk2 inhibitori i njihova upotreba |
| EP3242886A4 (en) | 2015-01-08 | 2018-08-29 | Moerae Matrix, Inc., | Formulation of mk2 inhibitor peptides |
| US10882867B2 (en) | 2017-03-16 | 2021-01-05 | Celgene Car Llc | Forms and compositions of a MK2 inhibitor |
| WO2018170200A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Heteroaryl compounds useful as mk2 inhibitors |
| WO2018170203A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Mk2 inhibitors, synthesis thereof, and intermediates thereto |
| EP3596085A4 (en) | 2017-03-16 | 2020-11-25 | Celgene CAR LLC | DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES |
| US11098057B2 (en) | 2017-03-16 | 2021-08-24 | Celgene Car Llc | 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof |
| WO2020236636A1 (en) | 2019-05-17 | 2020-11-26 | Celgene Car Llc | Methods of treating a mk2-mediated disorder |
| KR20230044446A (ko) | 2020-07-24 | 2023-04-04 | 브리스톨-마이어스 스큅 컴퍼니 | 급성 호흡기 장애의 치료 방법 |
-
2015
- 2015-09-16 RS RS20210725A patent/RS62017B1/sr unknown
- 2015-09-16 SM SM20210311T patent/SMT202100311T1/it unknown
- 2015-09-16 EP EP21164056.0A patent/EP3912981A1/en active Pending
- 2015-09-16 SG SG11201701861RA patent/SG11201701861RA/en unknown
- 2015-09-16 JP JP2017515845A patent/JP6556225B2/ja active Active
- 2015-09-16 LT LTEP15842903.5T patent/LT3193611T/lt unknown
- 2015-09-16 TW TW104130645A patent/TWI744217B/zh active
- 2015-09-16 AU AU2015317741A patent/AU2015317741B2/en active Active
- 2015-09-16 MA MA40534A patent/MA40534B1/fr unknown
- 2015-09-16 BR BR112017005266-0A patent/BR112017005266B1/pt active IP Right Grant
- 2015-09-16 ES ES15842903T patent/ES2874561T3/es active Active
- 2015-09-16 MX MX2017003359A patent/MX373341B/es active IP Right Grant
- 2015-09-16 SI SI201531617T patent/SI3193611T1/sl unknown
- 2015-09-16 PT PT158429035T patent/PT3193611T/pt unknown
- 2015-09-16 EA EA201790380A patent/EA037299B1/ru not_active IP Right Cessation
- 2015-09-16 CN CN201580058026.4A patent/CN106998692B/zh active Active
- 2015-09-16 WO PCT/US2015/050495 patent/WO2016044463A2/en not_active Ceased
- 2015-09-16 EP EP15842903.5A patent/EP3193611B1/en active Active
- 2015-09-16 HR HRP20210529TT patent/HRP20210529T1/hr unknown
- 2015-09-16 CA CA2961607A patent/CA2961607C/en active Active
- 2015-09-16 DK DK15842903.5T patent/DK3193611T3/da active
- 2015-09-16 PL PL15842903T patent/PL3193611T3/pl unknown
- 2015-09-16 KR KR1020177010439A patent/KR102457848B1/ko active Active
- 2015-09-16 US US14/856,311 patent/US9458175B2/en active Active
- 2015-09-16 HU HUE15842903A patent/HUE054347T2/hu unknown
- 2015-09-16 SG SG10201902326XA patent/SG10201902326XA/en unknown
-
2016
- 2016-09-29 US US15/280,157 patent/US9790235B2/en active Active
-
2017
- 2017-03-09 IL IL25105117A patent/IL251051B/en active IP Right Grant
- 2017-03-09 CL CL2017000576A patent/CL2017000576A1/es unknown
- 2017-03-14 MX MX2020005213A patent/MX2020005213A/es unknown
- 2017-03-16 SA SA517381115A patent/SA517381115B1/ar unknown
- 2017-04-04 CO CONC2017/0003279A patent/CO2017003279A2/es unknown
- 2017-04-13 EC ECIEPI201723281A patent/ECSP17023281A/es unknown
- 2017-10-13 US US15/782,995 patent/US10253040B1/en active Active
-
2019
- 2019-04-04 US US16/375,317 patent/US10577380B2/en active Active
- 2019-07-09 JP JP2019127476A patent/JP2019194236A/ja active Pending
-
2020
- 2020-02-27 US US16/802,654 patent/US11584757B2/en active Active
-
2021
- 2021-06-09 CY CY20211100504T patent/CY1124215T1/el unknown
-
2022
- 2022-03-16 JP JP2022041396A patent/JP7375072B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124215T1 (el) | Μκ2 αναστολεις και χρησεις αυτων | |
| CY1124131T1 (el) | Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου | |
| CY1124338T1 (el) | Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων | |
| MX2015008999A (es) | Inhibidores mk2 y usos de los mismos. | |
| MA46458A (fr) | Compositions debacillus thuringiensis | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| EA201790984A1 (ru) | Анти-cd79b антитела и способы их применения | |
| CL2016001871A1 (es) | Anticuerpos humanos para pd-1 | |
| BR112017003414A2 (pt) | composições compreendendo caseína e métodos para produzir as mesmas | |
| EA201790569A1 (ru) | Антитела и иммуноконъюгаты против cll-1 | |
| MX2016003843A (es) | Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
| TR201810635T4 (tr) | Anti-jagged1 antikorları ve kullanım yöntemleri. | |
| EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
| EA201891344A1 (ru) | Новые агонисты рецептора апелина и способы применения | |
| IL261904A (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists | |
| LT3594238T (lt) | Antikūno kompozicijos, skirtos navikų gydymui | |
| PH12016501873A1 (en) | Anti-influenza b virus hemagglutinin antibodies and methods of use | |
| CY1119489T1 (el) | Υποκατεστημενη πιπεριδυλο-αιθυλο-πυριμιδινη ως αναστολεας της ο-ακυλο τρανσφερασης της γκρελινης | |
| MX389447B (es) | Composiciones y métodos para anticuerpos dirigidos a bmp6. | |
| MX2018004674A (es) | Moduladores de interacción de sestrina-gator2 y sus usos. | |
| MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
| CY1122287T1 (el) | Ενωσεις χρησιμες για την αναστολη toy ror-γαμμα-τ | |
| EA201791992A1 (ru) | Ингибиторы грелин-o-ацилтрансферазы | |
| EA201792000A1 (ru) | Ингибиторы грелин-o-ацилтрансферазы | |
| JO3456B1 (ar) | فيروتيوكسيتين بيروجلوتامات |